Meeting
2015 ASCO Annual Meeting
A phase II study of axitinib in advanced carcinoid tumors: Preliminary results.
Authors
Mauro Cives
Moffitt Cancer Center and Research Institute, Tampa, FL
Mauro Cives , Jonathan R. Strosberg , Tiffany Campos , Thomas Weber , McKinley Nickerson , Chloe Evelyn Atreya , Alan P. Venook , Robin Kate Kelley , Tiffany Valone , Domenico Coppola , Emily K. Bergsland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT01435122
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4100)
DOI
10.1200/jco.2015.33.15_suppl.4100
Abstract #
4100
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
First Author: Jeffrey Graham
Poster
2012 ASCO Annual Meeting
PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the Arbeitsgemeinschaft internistische Onkologie (AIO).
First Author: Kirstin Breithaupt
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).
First Author: Austin Kalirai